Panna Sharma's guest appearances

Panna Sharma

Wall Street Unplugged - What's Really Moving These Markets

Finding Genius Podcast

Slice of Healthcare

FutureTech Podcast

BioBoss

Action and Ambition

Jo Bhakdi

David Freedman

Claudia Gray

Alessandra Sussulini

Robb Wolf

Katie Peichel

Tierra Biosciences

Elliot Roth

Matthew Lungren

Jane Antony

Luis P. Villarreal

Ellen Wermter

Andrew Koutnik

Eugene B. Chang

Darshan Shah

OwlTail

Welcome to another episode of The Action and Ambition Podcast! Joining us today is Panna Sharma, President, CEO and, Board Member of Lantern Pharma, Inc. Lantern Pharma is a clinical-stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data, and precision oncology trials. Panna was also the President and CEO of Cancer Genetics, Inc. A provider of genomic and immune-based cancer diagnostics and therapy development services. Tune in to learn more!

Welcome to another episode of The Action and Ambition Podcast! Joining us today is Panna Sharma, President, CEO and, Board Member of Lantern Pharma, Inc. Lantern Pharma is a clinical-stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data, and precision oncology trials. Panna was also the President and CEO of Cancer Genetics, Inc. A provider of genomic and immune-based cancer diagnostics and therapy development services. Tune in to learn more!

Panna Sharma on Leveraging Artificial Intelligence To Rescue and Develop Cancer Therapies

Our guest: Panna Sharma, CEO &amp; President at Lantern Pharma "Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer  drugs using machine learning techniques, genomic data and precision oncology trials."  In this episode, we discussed:  His background Lantern Pharma's why-how-what  Biden's drug pricing plan: what's missing and how can we take more steps to reform?  What can we expect from the future of AI in cancer treatment?  ...and much more!   Our sponsors for this episode are BlocHealth, Curation Health, ChenMed &amp; MediTelecare. BlocHealth is building the ecosystem of services and solutions to power the future of healthcare. For more information, please go to www.blochealth.com follow BlocHealth on social media - @blochealth "Curation Health’s advanced clinical decision support platform seamlessly integrates into the electronic health record and leverages more than 750 proven clinical and quality rules. With this intelligent point-of-care platform, you can power a scalable risk adjustment process and amplify quality program performance." For more information, please go to www.curationhealthcare.com &amp; follow Curation Health on social media - @curationhealth "ChenMed brings concierge-style medicine and better health outcomes to the neediest populations – moderate-to-low income seniors with complex chronic diseases. For more information, please go to www.chenmed.com &amp; follow ChenMed on social media - @chenmed "MediTelecare provides behavioral telemedicine services to residents of skilled nursing and assisted living facilities, using state-of-the-art telehealth technology. For more information", please go to www.meditelecare.com &amp; follow Meditelecare on social media – @meditelecare To learn more about Lantern Pharma please use the links below: - Website - LinkedIn - Twitter  Also, be sure to follow Slice of Healthcare on our social channels: - Website - Facebook - LinkedIn - Twitter - YouTube - Newsletter

Our guest: Panna Sharma, CEO &amp; President at <a href="https://www.lanternpharma.com/" rel="nofollow" target="_blank">Lantern Pharma</a> "Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer  drugs using machine learning techniques, genomic data and precision oncology trials." In this episode, we discussed: <ul> <li>His background</li> <li>Lantern Pharma's why-how-what </li> <li>Biden's drug pricing plan: what's missing and how can we take more steps to reform? </li> <li>What can we expect from the future of AI in cancer treatment? </li> <li>...and much more! </li> </ul> Our sponsors for this episode are <a href="https://www.blochealth.com/" rel="nofollow" target="_blank">BlocHealth</a>, <a href="https://curationhealthcare.com/" rel="ugc noopener noreferrer nofollow" target="_blank">Curation Health</a>, <a href="https://www.chenmed.com/" rel="ugc noopener noreferrer nofollow" target="_blank">ChenMed</a> &amp; <a href="https://www.meditelecare.com/" rel="ugc noopener noreferrer nofollow" target="_blank">MediTelecare</a>. BlocHealth is building the ecosystem of services and solutions to power the future of healthcare. For more information, please go to <a href="https://www.blochealth.com/" rel="nofollow" target="_blank">www.blochealth.com</a> follow BlocHealth on social media - @blochealth "Curation Health’s advanced clinical decision support platform seamlessly integrates into the electronic health record and leverages more than 750 proven clinical and quality rules. With this intelligent point-of-care platform, you can power a scalable risk adjustment process and amplify quality program performance." For more information, please go to <a href="https://curationhealthcare.com/" rel="nofollow" target="_blank">www.curationhealthcare.com</a> &amp; follow Curation Health on social media - @curationhealth "ChenMed brings concierge-style medicine and better health outcomes to the neediest populations – moderate-to-low income seniors with complex chronic diseases. For more information, please go to <a href="https://www.chenmed.com/" rel="nofollow" target="_blank">www.chenmed.com</a> &amp; follow ChenMed on social media - @chenmed "MediTelecare provides behavioral telemedicine services to residents of skilled nursing and assisted living facilities, using state-of-the-art telehealth technology. For more information", please go to <a href="https://www.meditelecare.com/" rel="nofollow" target="_blank">www.meditelecare.com</a> &amp; follow Meditelecare on social media – @meditelecare To learn more about Lantern Pharma please use the links below: - <a href="https://www.lanternpharma.com/" rel="nofollow" target="_blank">Website</a> - <a href="https://www.linkedin.com/company/lanternpharma/" rel="nofollow" target="_blank">LinkedIn</a> - <a href="https://twitter.com/lanternpharma?lang=en" rel="nofollow" target="_blank">Twitter </a> Also, be sure to follow Slice of Healthcare on our social channels: - <a href="//www.sliceofhealthcare.com" rel="nofollow" target="_blank">Website</a> - <a href="https://www.facebook.com/sliceofhealthcare/" rel="ugc noopener noreferrer nofollow" target="_blank">Facebook</a> - <a href="https://www.linkedin.com/company/vicarious-surgical/" rel="nofollow" target="_blank">LinkedIn</a> - <a href="https://twitter.com/SliceofHC" rel="ugc noopener noreferrer nofollow" target="_blank">Twitter</a> - <a href="https://www.youtube.com/channel/UCPuxsHtzFktm1XezuJp-KoA" rel="ugc noopener noreferrer nofollow" target="_blank">YouTube</a> - <a href="http://eepurl.com/g9qrU5" rel="ugc noopener noreferrer nofollow" target="_blank">Newsletter</a>

#192 - Panna Sharma, CEO & President at Lantern Pharma

Panna Sharma, CEO of Lantern Pharma, headquartered in Dallas, Texas, shares his thoughts with BioBoss host John Simboli about leadership and how Lantern is working at the intersection of artificial intelligence, genomics and machine learning to advance precision oncology therapies.

Panna Sharma, CEO of Lantern Pharma, headquartered in Dallas, Texas, shares his thoughts with BioBoss host John Simboli about leadership and how Lantern is working at the intersection of artificial intelligence, genomics and machine learning to advance precision oncology therapies.

#39 - Panna Sharma - CEO of Lantern Therapeutics

Not more than twenty years ago, only four or five blood cancers could be defined; today, hundreds of different types of lymphoma, leukemia, and myeloma cancers have been characterized—each one with a unique molecular structure and genome. As a result, an enormous amount of data has become available in the area of research and development for cancer drugs. According to Panna Sharma, CEO of Lantern Pharma, there is no better place to apply the tools of machine learning and artificial intelligence (AI). “There could be more permutations of chemical compounds than there are galaxies, so it’s a perfect problem area for AI,” says Sharma. He goes on to explain why some drugs—despite being extremely effective for some people—don’t stay on the market. In addition to depriving patients access to a drug which could truly help them, this also represents a significant financial loss, considering that hundreds of millions of dollars can go into the development of a single cancer drug. The technology being employed by Lantern Pharma has the ability to identify which drugs have worked for some people in the past, why they worked, and how to use this information as a predictive measure of what may (or may not) work for any given patient with a particular type of cancer. Sharma is a wealth of knowledge, and discusses the details of all this and more, including:  How many cancer drugs are already built in to the Lantern Pharma model How many gene expression profiles there are within a given tumor The importance of understanding a tumor’s response to a given drug and how Lantern Pharma is trying to elucidate this in prostate cancer  Learn more at https://www.lanternpharma.com/.

Not more than twenty years ago, only four or five blood cancers could be defined; today, hundreds of different types of lymphoma, leukemia, and myeloma cancers have been characterized—each one with a unique molecular structure and <a href="https://www.futuretechpodcast.com/podcasts/grasping-genome-nancy-j-kelley-jd-mpp-president-ceo-associates-genomic-research-implications-world/" rel="nofollow" target="_blank">genome</a>. As a result, an enormous amount of data has become available in the area of research and development for cancer drugs. According to Panna Sharma, CEO of Lantern Pharma, there is no better place to apply the tools of machine learning and artificial intelligence (AI). “There could be more permutations of chemical compounds than there are galaxies, so it’s a perfect problem area for AI,” says Sharma. He goes on to explain why some drugs—despite being extremely effective for some people—don’t stay on the market. In addition to depriving patients access to a drug which could truly help them, this also represents a significant financial loss, considering that hundreds of millions of dollars can go into the development of a single cancer drug. The technology being employed by Lantern Pharma has the ability to identify which drugs have worked for some people in the past, why they worked, and how to use this information as a predictive measure of what may (or may not) work for any given patient with a particular type of cancer. Sharma is a wealth of knowledge, and discusses the details of all this and more, including: <ul> <li>How many cancer drugs are already built in to the Lantern Pharma model</li> <li>How many gene expression profiles there are within a given tumor</li> <li>The importance of understanding a tumor’s response to a given drug and how Lantern Pharma is trying to elucidate this in prostate cancer</li> </ul> Learn more at <a href="https://www.lanternpharma.com/" rel="nofollow" target="_blank">https://www.lanternpharma.com/</a>.

Artificial Intelligence-Accelerated Development of Cancer Drugs—Panna Sharma—Lantern Pharma

“The premise of Lantern is to use the most current advances in machine learning, artificial intelligence, and genomics to help rescue and develop cancer drugs faster and cheaper and with lower risk so we can get them to patients in a more personalized manner,” says Panna Sharma, CEO of Lantern Pharma. Sharma was drawn to the premise of Lantern primarily because it just makes sense, given the tremendous amount of molecular and genomic data now available on hundreds of different types of cancers. The technology being employed by Lantern Pharma has the ability to identify which drugs have worked for some people in the past, why they worked, and how to predict which patients may benefit from them in the future. As a result, the Lantern Pharma technology is rescuing certain cancer drugs which have the potential to work extremely well for some patients, despite not making it to the market for being deemed not effective enough. They’re also using this technology to drive the development of new drugs. On today’s episode, you will discover:  How many cancer drugs are already built in to the Lantern Pharma model How many gene expression profiles there are within a given tumor The importance of understanding a tumor’s response to a given drug  Interested in learning more? Tune in and visit https://www.lanternpharma.com/.

“The premise of Lantern is to use the most current advances in machine learning, artificial intelligence, and <a href="https://www.futuretechhealth.com/podcasts/exploring-the-genome-and-behavior-of-parasites-dr-richard-mcculloch-university-of-glasgow/" rel="nofollow" target="_blank">genomics</a> to help rescue and develop cancer drugs faster and cheaper and with lower risk so we can get them to patients in a more personalized manner,” says Panna Sharma, CEO of Lantern Pharma. Sharma was drawn to the premise of Lantern primarily because it just makes sense, given the tremendous amount of molecular and genomic data now available on hundreds of different types of cancers. The technology being employed by Lantern Pharma has the ability to identify which drugs have worked for some people in the past, why they worked, and how to predict which patients may benefit from them in the future. As a result, the Lantern Pharma technology is rescuing certain cancer drugs which have the potential to work extremely well for some patients, despite not making it to the market for being deemed not effective enough. They’re also using this technology to drive the development of new drugs. On today’s episode, you will discover: <ul> <li>How many cancer drugs are already built in to the Lantern Pharma model</li> <li>How many gene expression profiles there are within a given tumor</li> <li>The importance of understanding a tumor’s response to a given drug</li> </ul> Interested in learning more? Tune in and visit <a href="https://www.lanternpharma.com/" rel="nofollow" target="_blank">https://www.lanternpharma.com/</a>.

Machine Learning and AI-Driven Development of Cancer Drugs—Panna Sharma—Lantern Pharma

Welcome back to another episode of Wall Street Unplugged! On today’s show, I introduce listeners to Panna Sharma. Panna is the CEO and President of a small-cap, clinical and diagnostics company - Cancer Genetics (CGIX). Panna brings together everything you need to know about the company. It’s core focus? Precision medicine. And the drug industry is betting big on it… To start off the interview, Panna and I talk about how treatments and innovations in the industry are rapidly changing… In the past, companies were betting on single drugs and routine treatments to cure all. But considering the complex, biological diversity of something like cancer, there has never been and never will be “one answer.” Panna explains how the industry and his company in particular are making huge strides in the right direction. Recently, we’ve seen a transfer from trial-and-error medicines to evidence-based medicine. And instead of dividing patients into groups based on thousands of outcomes, today you can now treat patients baseds on the details of their own unique genes. The trend is the death of “one size fits all.” And companies like Cancer Genetics are sitting at the center of it. The business model, as Panna says, comes from a “multi-tiered” approach. The company focuses on drug design, clinical trials, and diagnosis development. It’s a strategy leveraged from genomic data, innovation, and collaboration. And it benefits both side’s of the equation - the world of biotech/pharma development, as well as the patients. Now for those that are familiar with my podcast, you know that I’m picky... And you probably have heard about my show’s golden rule -- To never bring on a CEO of a company I don’t personally believe in. In other words, don’t take this as a sales pitch. This company, no doubt, has long-term growth potential. And Panna has all the right answers to back it up… After looking at what’s actually on paper, it was difficult to turn away. For one, there’s high insider ownership. But more important, Cancer Genetics is working with 8 out of the top 10 biotech companies. A small company with strong partnerships with some of the biggest names in the industry is huge. This commercial traction alone is their strongest catalyst going forward. The current share price is sitting just above $2.00. And valuations are at a steep discount compared to other traditional genomic diagnosis companies. But before taking any action, note that earnings are only one week away. And considering the current shape of the industry, be sure to do some homework. Again, this is a long-term play… And resources like this interview are a great place to start. Not only is this a company that should be on everyone’s radar, this is one of those “feel good” stories. And I’m more than happy to introduce listeners to the opportunity. Just click here to listen…